Cargando…
Tuning mTORC1 activity dictates the response of acute myeloid leukemia to LSD1 inhibition
Lysine specific demethylase-1 (LSD1) has been shown to be critical in acute myeloid leukemia (AML) pathogenesis and this has led to the development of LSD1 inhibitors (LSD1i) which are currently tested in clinical trials. Nonetheless, preclinical studies reported that AML cells frequently exhibit in...
Autores principales: | Abdel-Aziz, Amal Kamal, Pallavicini, Isabella, Ceccacci, Elena, Meroni, Giuseppe, Saadeldin, Mona Kamal, Varasi, Mario, Minucci, Saverio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ferrata Storti Foundation
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7395280/ https://www.ncbi.nlm.nih.gov/pubmed/31537694 http://dx.doi.org/10.3324/haematol.2019.224501 |
Ejemplares similares
-
Pharmacological inhibition of LSD1 triggers myeloid differentiation by targeting GSE1 oncogenic functions in AML
por: Nicosia, Luciano, et al.
Publicado: (2021) -
mTORC2 dictates Warburg effect and drug resistance
por: Masui, Kenta, et al.
Publicado: (2014) -
Targeting the scaffolding role of LSD1 (KDM1A) poises acute myeloid leukemia cells for retinoic acid–induced differentiation
por: Ravasio, Roberto, et al.
Publicado: (2020) -
Lysergic acid diethylamide (LSD) promotes social behavior through mTORC1 in the excitatory neurotransmission
por: De Gregorio, Danilo, et al.
Publicado: (2021) -
Pre-clinical activity of combined LSD1 and mTORC1 inhibition in MLL-translocated acute myeloid leukaemia
por: Deb, Gauri, et al.
Publicado: (2019)